Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C35H38N4O6.2ClH |
Molecular Weight | 683.621 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.Cl.COC(=O)C1=C(C)NC(C)=C([C@H]1C2=CC=CC(=C2)[N+]([O-])=O)C(=O)OCCN3CCN(CC3)C(C4=CC=CC=C4)C5=CC=CC=C5
InChI
InChIKey=JINNGBXKBDUGQT-GDCSGTLQSA-N
InChI=1S/C35H38N4O6.2ClH/c1-24-30(34(40)44-3)32(28-15-10-16-29(23-28)39(42)43)31(25(2)36-24)35(41)45-22-21-37-17-19-38(20-18-37)33(26-11-6-4-7-12-26)27-13-8-5-9-14-27;;/h4-16,23,32-33,36H,17-22H2,1-3H3;2*1H/t32-;;/m0../s1
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C35H38N4O6 |
Molecular Weight | 610.6994 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/28617978Curator's Comment: The description was created based on several sources, including
https://clinicaltrials.gov/ct2/show/NCT03106597 | https://www.ncbi.nlm.nih.gov/pubmed/10440102
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28617978
Curator's Comment: The description was created based on several sources, including
https://clinicaltrials.gov/ct2/show/NCT03106597 | https://www.ncbi.nlm.nih.gov/pubmed/10440102
Manidipine, (S)- is enantiomer of Manidipine a lipophilic, third-generation dihydropyridine calcium channel antagonist with a high degree of selectivity for the vasculature, thereby inducing marked peripheral vasodilation with negligible cardiodepression. Manidipine has different pharmacological effects and (S)-manidipine is shown to be about 30–80 times more potent than (R)-manidipine in its antihypertensive action and in the radioligand binding assay. Patch-clamp experiments revealed that the S-enantiomers of manidipine displayed a faster onset of action and produced a greater blockade than the R-enantiomer. Also, manidipine enantiomers have markedly different pharmacokinetics and the S/R ratio for (S)- and (R)-enantiomer concentrations is 2.0
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2095229 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10440102 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/11693466
Manidipine 10 to 40 mg once daily for 4 weeks
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10440102
GH3 cells were used for activity evaluation. the cells grown on glass coverslips were loaded with 5 mM 1-[2-(5-carboxyoxazol-2-yl)- 6-aminobenzofuran- 5-oxyx-2(-21-amino-51-methylphenoxy)-ethane-N,N,N1,N1-tetraace-tic acid pentaacetoxymethyl ester (fura-2AM) in Krebs–Ringer saline solution (5.5 mM KCl, 160 mM NaCl, 1.2 mM MgCl , 1.5 mM CaCl , 10 mM glucose, and 10 mM Hepes-NaOH, pH 7.4) for 1 h at room temperature. At the end of fura-2AM loading, the coverslip was introduced into a microscope chamber (Medical System, Greenvale, NY) on an inverted Nikon Diaphot fluorescence microscope. The cells were kept in Krebs–Ringer saline solution throughout the experiment. All the drugs tested were introduced into the microscope chamber by fast injection. When the depolarizing extracellular Kq solution (55 mM) was used, the osmolarity of the solution was kept constant by accordingly reducing the extracellular Naq concentration. A 100-W Xenon Lamp (Osram, Germany) with a computer-operated filter wheel bearing two different interference filters (340 and 380 nm) illuminated the microscopic field with UV light, alternating the wavelength at an interval of 500 ms. The interval between each pair of illuminations was 2 s, and the interval between filter movements was 1 s. Consequently, [Ca2++] was measured every 3 s. Emitted light was passed through a 400-nm dichroic mirror, filtered at 510 nm, and collected by a CCD camera connected to a light amplifier. Images were digitized and analyzed with a Magiscan image processor. Using a calibration curve, the Tardis software calculated the [Ca2++] corresponding to each pair of images from the ratio between the intensity of the light emitted when the cells were illuminated at both 340 and 380 nm.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 10:36:38 GMT 2023
by
admin
on
Sat Dec 16 10:36:38 GMT 2023
|
Record UNII |
E4997QG30G
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
E4997QG30G
Created by
admin on Sat Dec 16 10:36:38 GMT 2023 , Edited by admin on Sat Dec 16 10:36:38 GMT 2023
|
PRIMARY | |||
|
45358540
Created by
admin on Sat Dec 16 10:36:38 GMT 2023 , Edited by admin on Sat Dec 16 10:36:38 GMT 2023
|
PRIMARY | |||
|
119992-99-3
Created by
admin on Sat Dec 16 10:36:38 GMT 2023 , Edited by admin on Sat Dec 16 10:36:38 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
RACEMATE -> ENANTIOMER |